From Alzheimer’s to AI: Why Healthy Aging Is Turning Into an Economic Strategy at ASGH 2026

As populations age across Asia, Europe, and North America, healthcare systems are increasingly confronting a reality that extends far beyond hospitals and pharmaceuticals alone. Aging populations are driving rising healthcare costs, workforce shortages, long-term care burdens, and increasing rates of chronic disease and neurodegeneration. In response, governments, insurers, biotech companies, and technology firms are beginning to rethink healthcare itself — shifting away from reactive treatment models toward systems designed around prevention, prediction, and long-term functional health.

That shift became increasingly clear during a panel discussion on silver health and smart aging innovations at the Asia Summit on Global Health 2026, where leaders across longevity science, digital health, insurance, and AI outlined how healthcare systems may evolve over the next decade.

Rather than focusing solely on extending lifespan, much of the discussion centered on extending “healthspan” — the number of years individuals remain healthy, cognitively functional, independent, and economically active. The distinction matters because longer lifespans without functional health place growing strain on healthcare systems, families, labor markets, and national economies. Across the session, speakers repeatedly argued that the next phase of healthcare will depend less on isolated scientific breakthroughs and more on whether fragmented healthcare ecosystems can finally integrate.

Longevity Science Moves Beyond Theory

For decades, longevity research largely existed at the edges of academic science. Researchers could theorize about aging mechanisms, but lacked both the tools to measure biological aging accurately and the clinical infrastructure to intervene meaningfully. That is beginning to change.

Brian Kennedy, Distinguished Professor at the National University of Singapore and a leading longevity researcher, argued that the field is entering a fundamentally different era driven by two simultaneous developments: the rapid expansion of aging-focused interventions entering clinical trials, and the rise of biological aging clocks capable of measuring how quickly people are biologically aging.

“We now have everything from supplements to drugs, repurposed drugs, and a variety of other interventions that actually need to be tested in humans to see if they slow aging,” Kennedy said.

That capability changes the field substantially. Measuring biological age allows researchers to move beyond broad assumptions about chronological aging and instead evaluate whether interventions are actually slowing the underlying processes associated with disease, frailty, and cognitive decline.

Kennedy also emphasized that aging interventions will likely become increasingly personalized rather than universal.

“I don’t think any intervention is going to work in every person,” Kennedy said. “We need to be able to identify which people respond best to which interventions in order to maximize healthspan.”

The implication is significant. Longevity medicine may increasingly resemble precision oncology or personalized medicine more broadly — data-driven, predictive, and individualized rather than generalized. That transition could reshape not only healthcare delivery, but also insurance models, pharmaceutical development, and preventive medicine strategies.

Experts across longevity science, AI, insurance, biotech, and digital health explored how aging healthcare is shifting from reactive treatment toward predictive, system-wide prevention on Day 2 of ASGH in Hong Kong. Image: GeneOnline

Neurodegenerative Disease Is Moving Upstream

The discussion around neurodegenerative disease reflected how dramatically aging research is beginning to shift from symptom management toward prevention and early intervention. Bernard Gilly, CEO and co-founder of BrainEver, described aging itself as the primary risk factor behind diseases such as Alzheimer’s, Parkinson’s, ALS, and frontotemporal dementia.

“Our neurons are not renewing,” Gilly said. “They really are in need of a maintenance system.”

Because neurons do not regenerate like many other cells in the body, researchers are increasingly focused on preserving the internal systems that maintain neuronal stability — including DNA integrity, protein regulation, metabolic balance, and intracellular waste clearance. As those systems deteriorate with age, the risk of neurodegenerative disease rises sharply.

The broader significance of that research extends beyond treating disease after onset. Gilly argued that advances in biomarkers and molecular therapies could eventually allow clinicians to intervene before irreversible neurological decline begins.

That shift matters because neurodegenerative diseases represent one of the largest emerging economic and healthcare burdens globally. Effective early intervention could dramatically reduce long-term care costs, caregiver burden, and healthcare system strain — particularly as aging populations accelerate across developed economies.

AI Is Pushing Healthcare Toward Prediction

While biotechnology focused on biological aging, AI-focused discussions centered on prediction — specifically, how healthcare systems may begin identifying deterioration before symptoms become severe. Alex Mihailidis, Associate Vice-President at the University of Toronto and Scientific Director of AGE-WELL, argued that AI is fundamentally changing healthcare from a reactive system into a predictive one.

Historically, elder care technologies primarily responded after health crises occurred. Smart home systems detected falls, monitored movement, or triggered emergency alerts. But Mihailidis argued that AI systems are increasingly capable of predicting deterioration before those events happen.

“We want to be able to predict things like a fall or an infection before they even happen,” Mihailidis said.

He described research using speech analysis, behavioral monitoring, and daily activity patterns to identify cognitive decline months before conventional clinical assessments. By analyzing changes in routines, movement, and natural conversation, AI systems are beginning to function as non-invasive predictive biomarkers.

The importance of that shift is substantial. Earlier intervention not only improves patient outcomes, but also reduces hospitalization, long-term disability, and healthcare expenditures. Predictive systems could ultimately allow healthcare providers to intervene while patients remain fully functional rather than waiting until decline becomes severe.

Mihailidis also challenged the concept of “age-tech” itself, arguing that preventive technologies should become integrated throughout adulthood rather than introduced only once individuals become elderly.

“My smart watch when I was 64 is a smart watch,” he said. “When I turn 65 it’s now age-tech?”

That perspective reinforced a larger theme throughout the session: the future of aging healthcare may depend on embedding prevention continuously throughout life rather than treating aging as a separate healthcare category altogether.

Fragmentation Remains Healthcare’s Biggest Weakness

Despite rapid advances in AI and longevity science, speakers repeatedly identified fragmentation — not lack of innovation — as one of healthcare’s greatest structural failures. Kennedy pointed to the United States as an example of how advanced medicine and enormous healthcare spending can still produce poor population-level outcomes when systems remain politically fragmented and operationally disconnected.

“The life expectancy in that country is 60th in the world,” Kennedy said, calling it “an indictment of a healthcare system.”

His broader point was that healthcare systems often fail not because science is inadequate, but because incentives remain misaligned across hospitals, insurers, governments, regulators, and technology providers.

Similarly, Mihailidis argued that many promising technologies never move beyond academia because researchers focus too heavily on the technology itself while overlooking reimbursement structures, regulatory pathways, service delivery models, and commercialization ecosystems.

“I can build a fantastic robot for elder care,” Mihailidis said. “But if I don’t understand how that robot’s going to get into the hands and homes of older people who need them, and I don’t understand how systems are going to regulate it, then you’re not going to get anywhere.”

That ecosystem-focused thinking became one of the defining themes of the session. The panel repeatedly emphasized that future healthcare systems will require coordination between researchers, insurers, regulators, hospitals, digital platforms, and governments simultaneously — a challenge many healthcare systems still struggle to achieve.

China’s Digital Health Infrastructure Shows What Scale Looks Like

The panel also highlighted how digital infrastructure is beginning to reshape healthcare delivery at population scale in China. Zhang Junjie, Vice President of Ant Group and President of Ant Health, described how digital healthcare systems have evolved from simple payment tools into integrated healthcare platforms connecting insurance, hospitals, reimbursement systems, AI support, and chronic disease management.

According to Zhang, more than 900 million users now utilize digital medical insurance systems through mobile platforms in China, allowing reimbursement, hospital registration, payments, and report retrieval to happen digitally.

At the same time, AI is increasingly being used to scale physician access itself. Zhang described how AI-generated physician “avatars” are now handling millions of patient interactions while helping route more complex cases back to human specialists.

The scale of those systems matters because healthcare workforce shortages are emerging globally, particularly in aging societies. AI may increasingly become less about replacing physicians and more about extending limited clinical capacity across large populations.

Still, Zhang acknowledged that technological capability alone cannot solve healthcare problems.

“Technology can bring many benefits, but it has to fight against human nature,” he said.

That challenge has pushed companies toward behavioral and gamification strategies designed to encourage healthier habits such as exercise, sleep, and preventive monitoring. Zhang also emphasized that trust remains one of AI healthcare’s most difficult barriers, particularly when sensitive medical data and automated systems become deeply embedded in everyday care.

Financing Preventive Healthcare May Become the Next Major Shift

Several speakers argued that healthcare financing itself may require structural reinvention if healthy aging systems are to scale sustainably. Sarah Salvilla, Group Chief Health Officer at FWD Group, explained that insurers are increasingly shifting from reactive reimbursement models toward prevention-focused systems emphasizing predictive diagnostics, early intervention, and long-term health maintenance.

“We’re much more looking upstream,” Salvilla said.

She described collaborations involving AI-enabled early cancer detection and predictive metabolic health systems as examples of how insurers are attempting to extend healthspan while reducing long-term healthcare costs. The financial logic is increasingly straightforward: preventing disease is often dramatically cheaper than treating advanced illness after decline has already occurred.

Meanwhile, Kevin Lau, founder and senior advisor of Trinity Medical Group Limited, argued that healthcare financing itself may eventually evolve similarly to ESG investment frameworks, creating dedicated financial incentives around prevention and healthy aging.

Lau described healthcare as economically “super inelastic,” noting that people often undervalue health until severe illness emerges.

“If I’m asking a patient who is on their deathbed what is the value of your health and healthcare to you right now, that patient would tell me, I’d give you anything and everything,” Lau said.

That observation underscored one of the session’s broader themes: healthcare systems historically reward intervention after crisis, while future healthy aging models may increasingly reward prevention before crisis occurs.

Healthy Aging Is Becoming an Economic Strategy

By the end of the discussion, healthy aging had increasingly been framed not simply as a healthcare issue, but as a long-term economic strategy tied to workforce sustainability, healthcare expenditure, productivity, and national competitiveness.

Speakers repeatedly argued that the regions capable of integrating AI, preventive medicine, financing systems, digital infrastructure, and healthcare delivery into cohesive ecosystems may ultimately gain major advantages as populations age.

“This is not a medical problem,” Salvilla said. “This is a system delivery challenge.”

That idea ultimately defined the broader direction of the session. The future of healthy aging may depend less on discovering a single breakthrough therapy — and more on whether healthcare systems can coordinate science, infrastructure, financing, AI, prevention, and human behavior at population scale.

Author

Bernice Lottering